Overview

Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

Status:
Completed

Trial end date:
2013-10-11

Target enrollment:

Participant gender:

Summary

This is a multi-center, evaluator-blinded, randomized, comparative study designed to assess the safety, efficacy, and pharmacokinetics (PK) of daptomycin in pediatric subjects ages 1 to 17 years, inclusive, with complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens.

Phase:

Phase 4

Details

Lead Sponsor:

Cubist Pharmaceuticals LLC

Treatments:

Cloxacillin
Daptomycin
Nafcillin
Oxacillin